Is the randomized registry trial the next “disruptive technology” in clinical research? That is the question posed and discussed by Dr. Michael Lauer, director of the NHLBI’s Division of Cardiovascular Sciences, and co-author Dr. Ralph B. D’Agostino from Boston University and the Harvard Clinical Research Institute in their recent New England Journal of Medicine perspective article.
Drs. Lauer and D’Agostino argue that the use of observational registries in conducting clinical trials could, in fact, be a game changer, especially in the current fiscal climate. As an example, they cite a recently conducted successful registry-based randomized trial, the Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial.
